Sequana medical opinion of the 2022 half-year results and

Ghent, BelgiumSeptember 1st 2022 Sequana Medical SA (Euronext Brussels: SEQUA) (there “Company” Where “Sequana medicalI“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half-year results ended June 30, 2022 on Thursday, September 8, 2022.

The management team will host a conference call with live webcast at 3:00 p.m. CET / 9:00 a.m. EST on the day of the results.

The webcast can be accessed by registering on the Investors event page of the Sequana Medical website or by clicking here. To participate in the Q&A, please click here to register. Once registered, you will receive call numbers and a confirmation code. The webcast and conference call will be in English and a replay will be available on the Company’s website shortly thereafter.

For more information please contact:

Sequana Medical

Optimal strategic communications

About Sequana Medical

Sequana Medical NV is a pioneer in the treatment of drug-resistant fluid overload, a serious and common clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-known problem in these growing diseases, causing serious problems for the large number of patients for whom current medications are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, leading to major medical issues including increased mortality, repeated hospitalizations, severe pain, labored breathing, and reduced mobility that severely affect daily life. .

alphapump® and DSR® are Sequana Medical’s proprietary platforms that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits to patients and reducing costs to healthcare systems. Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and is headquartered in Ghent, Belgium. For more information, please visit

Important Regulatory Disclaimers

The alphapump® is vscurrently not approved in the United States or Canada. In the United States and Canada, the alphapump system is currently under clinical investigation (POSEIDON study) and is under study in adult patients with refractory or recurrent ascites due to cirrhosis. For more information on the POSEIDON clinic study see DSR® Therapy is still under development and it should be noted that any statements regarding safety and efficacy derive from ongoing preclinical and clinical studies. surveys that still need to be completed. RSD therapy is actually not approved for clinical research in the United States or Canada. There is no link between the DSR therapy and the ongoing investigations with the alphapump system in Europe, the United States or Canada.

To note: alphapump® is a registered trademark. DSR® and alphapump DSR® are registered trademarks in Benelux, China, EU, UK and Hong Kong.

Forward-looking statements

This press release may contain predictions, estimates or other information that could be considered forward-looking statements. These forward-looking statements are not guarantees of future performance. These forward-looking statements represent Sequana Medical’s current judgment of what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to issue updates or revisions to the forward-looking statements contained in this press release, except as specifically required by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the views of Sequana Medical only as of the date of this press release.

  • Press release_Results announcement_September 1, 2022_NL_vF

  • Press release_Results announcement_September 1, 2022_FR_vF

Comments are closed.